{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:30:40Z","timestamp":1755037840758},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T00:00:00Z","timestamp":1409616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/nrcardio.2014.127","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T10:01:04Z","timestamp":1409652064000},"page":"631-633","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["10 Years of progress in HF research\u2014what have we learned?"],"prefix":"10.1038","volume":"11","author":[{"given":"Henry","family":"Krum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"key":"BFnrcardio2014127_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss, A. J.  et al. Cardiac-resynchronization therapy for the prevention of heart failure events. N . Engl. J. Med. 361, 1329\u20131338 (2009).","journal-title":"N . Engl. J. Med."},{"key":"BFnrcardio2014127_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ejhf.115","volume":"16","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J.  et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur. J. Heart. Fail. 16, 817\u2013825 (2014).","journal-title":"Eur. J. Heart. Fail."},{"key":"BFnrcardio2014127_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg, K.  et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875\u2013885 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio2014127_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F.  et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2014127_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt, B.  et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383\u20131392 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2014127_CR6","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker, S. D.  et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436\u20132448 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2014127_CR7","first-page":"29","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink, J. R.  et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. L ancet 381, 29\u201339 (2013).","journal-title":"L ancet"},{"key":"BFnrcardio2014127_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup, M.  et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304\u2013313 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio2014127_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge, M.  et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310, 66\u201374 (2013).","journal-title":"JAMA"},{"key":"BFnrcardio2014127_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","volume":"35","author":"RW Troughton","year":"2014","unstructured":"Troughton, R. W.  et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur. Heart. J. 35, 1559\u20131567 (2014).","journal-title":"Eur. Heart. J."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2014.127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2014.127","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2014.127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:53:58Z","timestamp":1684468438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2014.127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["BFnrcardio2014127"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2014.127","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]},"assertion":[{"value":"2 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K. declares that he has received research grants from Bayer, Medtronic, Novartis, Pfizer, and Servier.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}